Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors Therapeutics – Pipeline Analysis – PhramaProff

Press Release

Glycogen synthase kinase 3 beta (GSK-3β) is an attractive target for the treatment of psychiatric disorders and neurodegenerative diseases. Many GSK-3β inhibitors have been developed for the treatment of different central nervous system disorders. But, for an effective therapy, high IC50 values should be avoided and ATP-competition should be reduced during enzyme-compound binding. Studies suggested that ATP non-competitive GSK-3 inhibitors such covalent inhibitors and allosteric modulators are emerging as a promising approach with better efficacy and safety.

Despite of many GSK-3β inhibitors in clinical studies, many challenges still remains. In a clinical study, certain adverse events caused by off-target activity of GSK-3β inhibitors were determined after the screening of compounds that bind to the ATP-competitive binding site conserved across a broad range of kinases. Thus, there is an urgent need of development of GSK-3β inhibitors that can selectively target individual pathways and differentiate between the non-phosphorylated and phosphorylated GSK-3β.

Request to Get the Sample Pages at:   https://www.pharmaproff.com/request-sample/1200

Company like AMO Pharma Ltd. is in the process of developing AMO-02 as a small molecule which acts as a GSK-3β inhibitor for the treatment of congenital myotonic dystrophy.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Read More…

About Pharma Proff

Pharma Proff, a brainchild of Prescient & Strategic (P&S) Intelligence Private Limited, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

We, at Pharma Proff, offer comprehensive reports in addition to providing pragmatic consultancy solutions to help our clients develop business strategies—critical to operations, R&D, product commercialization, and collaborations—that warrant enduring and sustainable results.

On the cusp of a new era that celebrates and lives by technology and holds immense potential for growth in the healthcare and pharmaceutical segments, we ensure our clients remain abreast of the changing industry landscape, comprehend the market dynamics analytically, and channelize their resources efficiently to maintain their stronghold in the market.

Contact:

Pharma Proff

Toll-free: +1-888-778-7886 (USA/Canada)

International: +1-347-960-6455

Email: [email protected]

Web: https://www.pharmaproff.com/

Connect with us: LinkedIn | Twitter | Facebook

This post was originally published on Financial Sector

Comments are closed.